Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC.

ABSTRACT:

Introduction

Despite radical intent therapy for patients with stage III non-small-cell lung cancer (NSCLC), cumulative incidence of brain metastases (BM) reaches 30%. Current risk stratification methods fail to accurately identify these patients. As radiomics features have been shown to have predictive value, this study aims to develop a model combining clinical risk factors with radiomics features for BM development in patients with radically treated stage III NSCLC.

Methods

Retrospective analysis of two prospective multicentre studies. Inclusion criteria: adequately staged [¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography (18-FDG-PET-CT), contrast-enhanced chest CT, contrast-enhanced brain magnetic resonance imaging/CT] and radically treat

SUBMITTER: Keek SA 

PROVIDER: S-EPMC9403451 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature